Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excellence in Hematopoietic Stem Cell Transplantation

By HEOR Staff Writer

April 5, 2023

Abu Dhabi Stem Cells Center (ADSCC), a subsidiary of PureHealth, has been named a centre of excellence in Hematopoietic Stem Cell Transplantation by the Department of Health – Abu Dhabi. The centre provides specialised and distinguished programmes with a high level of expertise and multidisciplinary resources, allowing it to conduct advanced medical procedures in specific clinical areas and conducting complex researches to provide the highest levels of care. The centre will provide an integrated and specialised range of surgical and non-surgical clinical services with world-class healthcare quality for patients who require hematopoietic stem cell transplantation for the treatment of blood diseases. To date, 13 cancer patients and one MS female patient have been treated by ADSCC under the AD-BMT programme.

Reference url

Recent Posts

Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung Cancer

By HEOR Staff Writer

April 15, 2026

The FDA’s Priority Review of ifinatamab deruxtecan was recently announced, a potential first-in-class B7-H3 targeted therapy. The Biologics License Application for ifinatamab deruxtecan (I-DXd), a B7-H3 directed DXd antibody drug conjugate (ADC), has been accepted with a Prescription Drug User Fe...
Advancing Access: Generic Dapagliflozin Approval Enhanced for Type 2 Diabetes Treatment

By João L. Carapinha

April 14, 2026

The U.S. Food and Drug Administration has issued the generic dapagliflozin approval, clearing the first generic versions of FARXIGA (dapagliflozin) tablets. This decision significantly improves affordability and access to an important SGLT2 inhibitor for adults with type 2 diabetes. ...
Semaglutide Distribution Flexibility: EMA Approves Room Temperature Delivery for Wegovy®

By João L. Carapinha

April 13, 2026

The European Medicines Agency (EMA) has granted an important update to the product information for Wegovy (semaglutide), introducing semaglutide distribution flexibility that allows controlled-temperature delivery at up to 30°C for up to 48 hours during the final leg from pharmacies to patients. ...